Trial · NCT02725177
Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
NCT02725177, Not applicable, Completed, The Cleveland Clinic; results first posted 2023-02-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ocular Sarcoidosis Open Label Trial of ACTHAR Gel. Trials, record NCT02725177. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02725177
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
- NCT number
- NCT02725177
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 9 participants, actual
- Lead sponsor
- The Cleveland Clinic
- Conditions
- Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
- Interventions
- Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
- First posted
- 2016-03-31
- Last updated
- 2023-11-14
- Results first posted
- 2023-02-15
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Clinically Significant Improvement in Visual Acuity | Measured at 24 weeks | The primary outcome was percentage of patients meeting at least one of the following variables 1) improved visual acuity, 2) resolution of intraocular inflammation, 3) ability to taper ocular or oral steroids by at least 50% or 4) reduction of cystoid macular edema, with no worsening of any single one and no need for additional sarcoidosis therapies at 24 weeks . |
| Secondary | Percentage of Patients With Clinically Significant Improvement in the Resolution-intraocular Inflammation | Measured at 24 weeks | |
| Secondary | Proportion of Patients Experiencing a Tapering of Ocular/Oral Steroids by at Least 50% | Measured at 24 weeks | |
| Secondary | Proportion of Patients With a Clinically Significant Reduction-cystoid Macular Edema | Measured at 24 weeks |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Clinically Significant Improvement in Visual Acuity | Measured at 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients With Clinically Significant Improvement in the Resolution-intraocular Inflammation | Measured at 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Proportion of Patients Experiencing a Tapering of Ocular/Oral Steroids by at Least 50% | Measured at 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Proportion of Patients With a Clinically Significant Reduction-cystoid Macular Edema | Measured at 24 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients With Clinically Significant Improvement in Visual Acuity | H.P. Achtar Gel 80 U | 3 | Participants | ||
| Percentage of Patients With Clinically Significant Improvement in the Resolution-intraocular Inflammation | H.P. Achtar Gel 80 U | 2 | Participants | ||
| Proportion of Patients Experiencing a Tapering of Ocular/Oral Steroids by at Least 50% | H.P. Achtar Gel 80 U | 2 | Participants | ||
| Proportion of Patients With a Clinically Significant Reduction-cystoid Macular Edema | H.P. Achtar Gel 80 U | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | H.P. Achtar Gel 80 U | 9 | |
| Overall Study | COMPLETED | H.P. Achtar Gel 80 U | 4 | |
| Overall Study | NOT COMPLETED | H.P. Achtar Gel 80 U | 5 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fluid Retention | Vascular disorders | H.P. Achtar Gel 80 U | 7 | 9 | |
| other | Insomnia | General disorders | H.P. Achtar Gel 80 U | 4 | 9 | |
| other | Hypertension | Vascular disorders | H.P. Achtar Gel 80 U | 4 | 9 | |
| other | Depression | Psychiatric disorders | H.P. Achtar Gel 80 U | 3 | 9 | |
| other | Impaired Blood Sugar | Metabolism and nutrition disorders | H.P. Achtar Gel 80 U | 3 | 9 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | H.P. Achtar Gel 80 U | 0 | 9 |
| Total, other adverse events | H.P. Achtar Gel 80 U | 7 | 9 |
| Total, serious adverse events | H.P. Achtar Gel 80 U | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02725177
GET https://conductscience.org/api/trials/v1/NCT02725177/registered